Compare Inovio Pharmaceuticals Inc (INO) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Johnson Controls International PLC trades at $142.57 (market cap $85.03B). The key difference: Johnson Controls International PLC is far larger — about 952.5× Inovio Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | JCI | |
|---|---|---|
Market Cap | $89.27M | $85.03B |
Sector | Health | Industrials |
52-Week High | $2.87 | $148.21 |
52-Week Low | $1.05 | $103.24 |
Enterprise Value | $60.28M | $93.86B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Johnson Controls (JCI) trades at $139.03, down 1.02% today, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.19 versus $1.12, maintaining a pattern of earnings outperformance. Recent corporate developments include a $0.40 dividend declaration and board appointments, while cash flow trends show improvement with projected positive net cash flow of $157M for 2026.
JCI presents a compelling investment case with 62% analyst buy ratings and a $158.29 consensus price target offering 14% upside. However, elevated valuation multiples (P/E 42.95, EV/EBITDA 26.89) and bearish technical signals warrant caution. Key risks include competitive pressures in building technologies and sensitivity to commercial construction cycles, balanced by strong profitability margins and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
